Comments Regarding Identification, Assessment, and Control of Nitrosamine Drug Substance-Related Impurities in Human Drug Products Share page: Docket Number: FDA-2023-N-1585-0001 Download Document Issues: OTC Medicines Other Issues Quality Related Posts Press Releases and Statements Tennessee Expands Access to OTC Cold & Allergy Medications Containing PSE May 7, 2024 Press Releases and Statements CHPA Response to Study Examining Prescription Acid Reflux Drugs Apr 25, 2024 Articles Polibrief: Consumer Data Privacy: State Efforts to Preserve Privacy Apr 16, 2024